{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:51:10Z","timestamp":1791600670648,"version":"4.3.4"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The challenge of early detection and stratification in Parkinson\u2019s disease (PD) is urgent due to the current emergence of mechanism-based disease-modifying treatments. In here, metabolomic and lipidomic parameters obtained by a standardized and targeted in vitro diagnostic research (IVDr) platform have a significant potential to address therapy-related questions and generate improved biomarker panels. Our study aimed to use IVDr nuclear magnetic resonance (NMR) spectroscopy to quantify metabolites and lipoproteins in PD blood serum from different cohorts to stratify metabolically driven subtypes of idiopathic and genetic PD. Serum aliquots from three neurodegeneration biobank cohorts (287 samples in total, including 62 PD patient samples with GBA mutation, 98\/43 PD patient samples of early\/late stages of disease duration, 20 PD samples from patients with mutations in recessive PD genes and some smaller subgroups of mitochondrial and double mutation cases) were prepared and analyzed with IVDr NMR spectroscopy, covering 39 blood serum metabolites and 112 lipoprotein parameters. Uni- and multivariate statistics were used to identify metabolism-driven changes under consideration of typical confounders such as age, sex and disease duration and set into context with clinical biomarkers such as CSF concentrations of alpha-synuclein, neurofilament light chain, and tau protein. Based on the different PD subgroups we performed a total of eight different comparisons. Highlights from these comparisons include increased citrate and dimethylglycine with a decrease of creatinine and methionine in healthy controls and early PD group compared to GBA, PD late and recessive PD. We furthermore identified decreased HDL-3 free cholesterol in genetic PD cases compared to sporadic subject samples (sum of the PD early and PD late groups). Considering medication, we found that the levodopa equivalent daily dose (LEDD) is mostly positively correlated with tyrosine and citrate in sporadic PD compared to pyruvate and phenylalanine in genetic PD. Cerebrospinal fluid levels of alpha-synuclein were negatively correlated with alanine. Further metabolites and lipoproteins with discriminatory power for double mutation PD cases involved ornithine, 2-aminobutyrate and 2-hydroxybutyrate as well as for mitochondrial phenotypes via LDL phospholipid, apolipoprotein and cholesterol subfractions. Quantitative IVDr NMR serum spectroscopy is able to stratify PD patient samples of different etiology and can contribute to a wider understanding of the underlying metabolism-driven alterations e.g. in energy, amino acid, and lipoprotein metabolism. Though our overall cohort was large, major confounders such as age, sex and medication have a strong impact. That is why absolute quantification and detailed patient knowledge about metabolic confounders, is a premise for future translation of NMR serum spectroscopy to routine PD diagnostics.<\/jats:p>","DOI":"10.1038\/s41598-025-01352-0","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T02:16:41Z","timestamp":1747880201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of IVDr NMR spectroscopy to stratify Parkinson\u2019s disease with absolute quantitation of blood serum metabolites and lipoproteins"],"prefix":"10.1038","volume":"15","author":[{"given":"Georgy","family":"Berezhnoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuntae","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cannet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"J\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike Jakob","family":"Spruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Hellmann-Regen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Roeske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"P\u00fcrner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Glanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hufschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kilimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Dinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okka","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"D\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"van Riesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"W\u00fcllner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Falkenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"B\u00e4hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor C.","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rizzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Brosseron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1352_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","volume":"20","author":"F Richter","year":"2023","unstructured":"Richter, F., Stanojlovic, M., K\u00e4ufer, C., Gericke, B. & Feja, M. A mouse model to test novel therapeutics for Parkinson\u2019s disease: an update on the Thy1-aSyn (line 61) mice. Neurotherapeutics 20, 97\u2013116 (2023).","journal-title":"Neurotherapeutics"},{"key":"1352_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.24956","volume":"27","author":"B Mollenhauer","year":"2012","unstructured":"Mollenhauer, B. & Zhang, J. Biochemical premotor biomarkers for Parkinson\u2019s disease. Mov. Disord. 27, 644\u2013650 (2012).","journal-title":"Mov. Disord."},{"key":"1352_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1515\/cclm-2014-0783","volume":"53","author":"R Ren","year":"2015","unstructured":"Ren, R., Sun, Y., Zhao, X. & Pu, X. Recent advances in biomarkers for Parkinson\u2019s disease focusing on biochemicals, omics and neuroimaging. Clin. Chem. Lab. Med. (CCLM). 53, 1495\u20131506 (2015).","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","volume":"72","author":"M Beavan","year":"2015","unstructured":"Beavan, M. et al. Evolution of prodromal clinical markers of Parkinson disease in a GBA Mutation\u2013Positive cohort. JAMA Neurol. 72, 201\u2013208 (2015).","journal-title":"JAMA Neurol."},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s10571-023-01362-4","volume":"43","author":"SK Yadav","year":"2023","unstructured":"Yadav, S. K. et al. Transcriptomics and proteomics approach for the identification of altered blood MicroRNAs and plasma proteins in Parkinson\u2019s disease. Cell. Mol. Neurobiol. 43, 3527\u20133553 (2023).","journal-title":"Cell. Mol. Neurobiol."},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12920-016-0164-y","volume":"9","author":"A Dumitriu","year":"2016","unstructured":"Dumitriu, A. et al. Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. BMC Med. Genom. 9, 5 (2016).","journal-title":"BMC Med. Genom."},{"key":"1352_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trac.2019.05.047","volume":"118","author":"P G\u0105tarek","year":"2019","unstructured":"G\u0105tarek, P., Pawe\u0142czyk, M., Jastrz\u0119bski, K., G\u0142\u0105bi\u0144ski, A. & Ka\u0142u\u017cna-Czapli\u0144ska, J. Analytical methods used in the study of Parkinson\u2019s disease. TRAC Trends Anal. Chem. 118, 292\u2013302 (2019).","journal-title":"TRAC Trends Anal. Chem."},{"key":"1352_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","volume":"14","author":"Y Shao","year":"2019","unstructured":"Shao, Y. & Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol. Neurodegeneration. 14, 3 (2019).","journal-title":"Mol. Neurodegeneration"},{"key":"1352_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/mas.21553","volume":"38","author":"H Luan","year":"2019","unstructured":"Luan, H., Wang, X. & Cai, Z. Mass spectrometry-based metabolomics: targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders. Mass. Spectrom. Rev. 38, 22\u201333 (2019).","journal-title":"Mass. Spectrom. Rev."},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.aca.2012.05.049","volume":"750","author":"A Smolinska","year":"2012","unstructured":"Smolinska, A., Blanchet, L., Buydens, L. M. C. & Wijmenga, S. S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: A review. Anal. Chim. Acta. 750, 82\u201397 (2012).","journal-title":"Anal. Chim. Acta"},{"key":"1352_CR12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1021\/ac0517085","volume":"78","author":"ME Dumas","year":"2006","unstructured":"Dumas, M. E. et al. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for Large-Scale epidemiological research: the INTERMAP study. Anal. Chem. 78, 2199\u20132208 (2006).","journal-title":"Anal. Chem."},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-021-00274-8","volume":"8","author":"G Meoni","year":"2022","unstructured":"Meoni, G. et al. Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de Novo drug-naive Parkinson\u2019s disease patients. Npj Parkinson\u2019s Disease. 8, 14 (2022).","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.3390\/app12188954","volume":"12","author":"GM Dimitri","year":"2022","unstructured":"Dimitri, G. M., Meoni, G., Tenori, L., Luchinat, C. & Li\u00f3, P. NMR spectroscopy combined with machine learning approaches for age prediction in healthy and Parkinson\u2019s disease cohorts through metabolomic fingerprints. Appl. Sci. 12, 8954 (2022).","journal-title":"Appl. Sci."},{"key":"1352_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11306-019-1554-x","volume":"15","author":"J Troisi","year":"2019","unstructured":"Troisi, J. et al. A metabolomic signature of treated and drug-na\u00efve patients with Parkinson\u2019s disease: a pilot study. Metabolomics 15, 90 (2019).","journal-title":"Metabolomics"},{"key":"1352_CR121","doi-asserted-by":"crossref","unstructured":"Berezhnoy, G., Laske, C. & Trautwein, C. Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer\u2019s disease patients. Front. Aging Neurosci. 15, 1219718 (2023).","DOI":"10.3389\/fnagi.2023.1219718"},{"key":"1352_CR16","doi-asserted-by":"crossref","unstructured":"Berezhnoy, G., Laske, C. & Trautwein, C. Quantitative NMR-Based Lipoprotein Analysis Identifies Elevated HDL-4 and Triglycerides in the Serum of Alzheimer\u2019s Disease Patients. Int. J. Mol. Sci. 23, 12472 (2022).","DOI":"10.3390\/ijms232012472"},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/alz.12484","volume":"18","author":"L Jia","year":"2022","unstructured":"Jia, L. et al. A metabolite panel that differentiates Alzheimer\u2019s disease from other dementia types. Alzheimer\u2019s Dement. 18, 1345\u20131356 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or, Z. et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84, 880\u2013887 (2015).","journal-title":"Neurology"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh, Y. E. et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI. Npj Parkinson\u2019s Disease. 7, 102 (2021).","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3892\/ijo.2017.3885","volume":"50","author":"M Konno","year":"2017","unstructured":"Konno, M. et al. The one-carbon metabolism pathway highlights therapeutic targets for Gastrointestinal cancer (Review). Int. J. Oncol. 50, 1057\u20131063 (2017).","journal-title":"Int. J. Oncol."},{"key":"1352_CR21","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang, Z. et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 52, W398\u2013W406 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1352_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JPD-171127","volume":"7","author":"M Andr\u00e9asson","year":"2017","unstructured":"Andr\u00e9asson, M., Brodin, L., Laffita-Mesa, J. M. & Svenningsson, P. Correlations between methionine cycle metabolism, COMT genotype, and polyneuropathy in L-Dopa treated Parkinson\u2019s disease: A preliminary Cross-Sectional study. J. Parkinson\u2019s Disease. 7, 619\u2013628 (2017).","journal-title":"J. Parkinson\u2019s Disease"},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1039\/D4FO01613K","volume":"15","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. High methionine intake alters gut microbiota and lipid profile and leads to liver steatosis in mice. Food Funct. 15, 8053\u20138069 (2024).","journal-title":"Food Funct."},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1039\/C9FO00766K","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Dietary methionine restriction improves the gut microbiota and reduces intestinal permeability and inflammation in high-fat-fed mice. Food Funct. 10, 5952\u20135968 (2019).","journal-title":"Food Funct."},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto, V., Jenkinson, C., Fitzpatrick, R. & Greenhall, R. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual. Life Res. 4, 241\u2013248 (1995).","journal-title":"Qual. Life Res."},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/jnnp.2006.111161","volume":"78","author":"P Hagell","year":"2007","unstructured":"Hagell, P. & Nygren, C. The 39 item Parkinson\u2019s disease questionnaire (PDQ-39) revisited: implications for evidence based medicine. J. Neurol. Neurosurg. Psychiatry. 78, 1191\u20131198 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.20792","volume":"21","author":"M Visser","year":"2006","unstructured":"Visser, M., Leentjens, A. F. G., Marinus, J., Stiggelbout, A. M. & van Hilten, J. J. Reliability and validity of the Beck depression inventory in patients with Parkinson\u2019s disease. Mov. Disord. 21, 668\u2013672 (2006).","journal-title":"Mov. Disord."},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT BECK","year":"1961","unstructured":"BECK, A. T., WARD, C. H. & MENDELSON, M. ERBAUGH, J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4, 561\u2013571 (1961).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2015","unstructured":"Mart\u00ednez-Mart\u00edn, P. et al. Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s disease rating scale. Parkinsonism Relat. Disord. 21, 50\u201354 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1352_CR31","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"MD Disease","year":"2003","unstructured":"Disease, M. D. S.T.F.o.R.S.f.P.s. The unified Parkinson\u2019s disease rating scale (UPDRS): status and recommendations. Mov. Disord. 18, 738\u2013750 (2003).","journal-title":"Mov. Disord."},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1352_CR33","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"1352_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1352_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1474-4422(16)00071-5","volume":"15","author":"KY Mok","year":"2016","unstructured":"Mok, K. Y. et al. Deletions at 22q11.2 in idiopathic Parkinson\u2019s disease: a combined analysis of genome-wide association data. Lancet Neurol. 15, 585\u2013596 (2016).","journal-title":"Lancet Neurol."},{"key":"1352_CR36","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees, A. J., Hardy, J. & Revesz, T. Parkinson\u2019s disease. Lancet 373, 2055\u20132066 (2009).","journal-title":"Lancet"},{"key":"1352_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 20, 385\u2013397 (2021).","journal-title":"Lancet Neurol."},{"key":"1352_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg, D. et al. Prodromal Parkinson disease subtypes \u2014 key to Understanding heterogeneity. Nat. Rev. Neurol. 17, 349\u2013361 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1352_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00702-018-1910-4","volume":"125","author":"I Cova","year":"2018","unstructured":"Cova, I. & Priori, A. Diagnostic biomarkers for Parkinson\u2019s disease at a glance: where are we? J. Neural Transm. 125, 1417\u20131432 (2018).","journal-title":"J. Neural Transm"},{"key":"1352_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41582-022-00674-1","volume":"18","author":"H Teymourian","year":"2022","unstructured":"Teymourian, H. et al. Closing the loop for patients with Parkinson disease: where are we? Nat. Rev. Neurol. 18, 497\u2013507 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1352_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/acn3.489","volume":"4","author":"M San Luciano","year":"2017","unstructured":"San Luciano, M. et al. Sex differences in LRRK2 G2019S and idiopathic Parkinson\u2019s disease. Ann. Clin. Transl Neurol. 4, 801\u2013810 (2017).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"1352_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.genm.2011.05.002","volume":"8","author":"R Saunders-Pullman","year":"2011","unstructured":"Saunders-Pullman, R., Wang, C., Stanley, K. & Bressman, S. B. Diagnosis and referral delay in women with Parkinson\u2019s disease. Gend. Med. 8, 209\u2013217 (2011).","journal-title":"Gend. Med."},{"key":"1352_CR43","doi-asserted-by":"crossref","unstructured":"Lerche, S. et al. CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers. Front. Neurol. 13, 834580 (2022).","DOI":"10.3389\/fneur.2022.834580"},{"key":"1352_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","volume":"51","author":"LP Dolgacheva","year":"2019","unstructured":"Dolgacheva, L. P., Berezhnov, A. V., Fedotova, E. I., Zinchenko, V. P. & Abramov, A. Y. Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease. J. Bioenerg. Biomembr. 51, 175\u2013188 (2019).","journal-title":"J. Bioenerg. Biomembr."},{"key":"1352_CR45","doi-asserted-by":"publisher","first-page":"e9367","DOI":"10.1371\/journal.pone.0009367","volume":"5","author":"G Krebiehl","year":"2010","unstructured":"Krebiehl, G. et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson\u2019s Disease-Associated protein DJ-1. PLoS ONE. 5, e9367 (2010).","journal-title":"PLoS ONE"},{"key":"1352_CR46","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1371\/journal.pbio.0020362","volume":"2","author":"S Shendelman","year":"2004","unstructured":"Shendelman, S., Jonason, A., Martinat, C., Leete, T. & Abeliovich, A. DJ-1 is a Redox-Dependent molecular chaperone that inhibits \u03b1-Synuclein aggregate formation. PLoS Biol. 2, e362 (2004).","journal-title":"PLoS Biol."},{"key":"1352_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cells13040296","volume":"13","author":"LD Skou","year":"2024","unstructured":"Skou, L. D., Johansen, S. K., Okarmus, J. & Meyer, M. Pathogenesis of DJ-1\/PARK7-Mediated Parkinson\u2019s disease. Cells 13, 296 (2024).","journal-title":"Cells"},{"key":"1352_CR48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10571-018-0584-7","volume":"38","author":"C Cid-Castro","year":"2018","unstructured":"Cid-Castro, C., Hern\u00e1ndez-Espinosa, D. R. & Mor\u00e1n, J. ROS as regulators of mitochondrial dynamics in neurons. Cell. Mol. Neurobiol. 38, 995\u20131007 (2018).","journal-title":"Cell. Mol. Neurobiol."},{"key":"1352_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneurol.2014.228","volume":"11","author":"F Burt\u00e9","year":"2015","unstructured":"Burt\u00e9, F., Carelli, V. & Chinnery, P. F. Yu-Wai-Man, P. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol. 11, 11\u201324 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"1352_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","volume":"40","author":"BJ Ryan","year":"2015","unstructured":"Ryan, B. J., Hoek, S., Fon, E. A. & Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from Familial to sporadic disease. Trends Biochem. Sci. 40, 200\u2013210 (2015).","journal-title":"Trends Biochem. Sci."},{"key":"1352_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13024-017-0212-x","volume":"12","author":"DN Hauser","year":"2017","unstructured":"Hauser, D. N. et al. Hexokinases link DJ-1 to the PINK1\/parkin pathway. Mol. Neurodegener. 12, 70 (2017).","journal-title":"Mol. Neurodegener"},{"key":"1352_CR52","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.3390\/ijms24087409","volume":"24","author":"ME Sun","year":"2023","unstructured":"Sun, M. E. & Zheng, Q. The Tale of DJ-1 (PARK7): A Swiss army knife in biomedical and psychological research. IJMS 24, 7409 (2023).","journal-title":"IJMS"},{"key":"1352_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2009.10.025","volume":"390","author":"T Hayashi","year":"2009","unstructured":"Hayashi, T. et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem. Biophys. Res. Commun. 390, 667\u2013672 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1352_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jnr.21831","volume":"87","author":"E Junn","year":"2009","unstructured":"Junn, E., Jang, W. H., Zhao, X., Jeong, B. S. & Mouradian, M. M. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J. Neurosci. Res. 87, 123\u2013129 (2009).","journal-title":"J. Neurosci. Res."},{"key":"1352_CR55","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0955-2863(98)00022-9","volume":"9","author":"AM Wade","year":"1998","unstructured":"Wade, A. M. & Tucker, H. N. Antioxidant characteristics of L-histidine. J. Nutr. Biochem. 9, 308\u2013315 (1998).","journal-title":"J. Nutr. Biochem."},{"key":"1352_CR56","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/nu12030848","volume":"12","author":"M Hole\u010dek","year":"2020","unstructured":"Hole\u010dek, M. Histidine in health and disease: metabolism, physiological importance, and use as a supplement. Nutrients 12, 848 (2020).","journal-title":"Nutrients"},{"key":"1352_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/antiox10091467","volume":"10","author":"M Catanesi","year":"2021","unstructured":"Catanesi, M. et al. L-Methionine protects against oxidative stress and mitochondrial dysfunction in an in vitro model of Parkinson\u2019s disease. Antioxidants 10, 1467 (2021).","journal-title":"Antioxidants"},{"key":"1352_CR58","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/biomedicines9121944","volume":"9","author":"KH Chang","year":"2021","unstructured":"Chang, K. H. et al. Altered metabolic profiles of the plasma of patients with amyotrophic lateral sclerosis. Biomedicines 9, 1944 (2021).","journal-title":"Biomedicines"},{"key":"1352_CR59","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1111\/ene.16041","volume":"30","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Comparison of biospecimens for \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease: A systematic review and network meta-analysis. Eur. J. Neurol. 30, 3949\u20133967 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1352_CR60","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13054-021-03698-z","volume":"25","author":"CA Santacruz","year":"2021","unstructured":"Santacruz, C. A. et al. Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature. Crit. Care. 25, 278 (2021).","journal-title":"Crit. Care"},{"key":"1352_CR61","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi, A. et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448\u20131455 (2023).","journal-title":"Nat. Med."},{"key":"1352_CR62","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge, A. et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain 145, 3058\u20133071 (2022).","journal-title":"Brain"},{"key":"1352_CR63","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","volume":"38","author":"M Xylaki","year":"2023","unstructured":"Xylaki, M. et al. Extracellular vesicles for the diagnosis of Parkinson\u2019s disease: systematic review and Meta-Analysis. Mov. Disord. 38, 1585\u20131597 (2023).","journal-title":"Mov. Disord."},{"key":"1352_CR64","doi-asserted-by":"crossref","unstructured":"Xie, H. et al. Abnormalities of cerebral blood flow and the regional brain function in Parkinson\u2019s disease: a systematic review and multimodal neuroimaging meta-analysis. Front. Neurol. 14, 1289934 (2023).","DOI":"10.3389\/fneur.2023.1289934"},{"key":"1352_CR65","doi-asserted-by":"publisher","first-page":"127190","DOI":"10.1016\/j.jtemb.2023.127190","volume":"78","author":"Y Xu","year":"2023","unstructured":"Xu, Y., Huang, X., Geng, X. & Wang, F. Meta-analysis of iron metabolism markers levels of Parkinson\u2019s disease patients determined by fluid and MRI measurements. J. Trace Elem. Med Biol. 78, 127190 (2023).","journal-title":"J. Trace Elem. Med Biol."},{"key":"1352_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cca.2020.08.005","volume":"510","author":"S Kumari","year":"2020","unstructured":"Kumari, S. et al. Identification of potential urine biomarkers in idiopathic Parkinson\u2019s disease using NMR. Clin. Chim. Acta. 510, 442\u2013449 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"1352_CR67","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41531-024-00732-z","volume":"10","author":"X Luo","year":"2024","unstructured":"Luo, X., Liu, Y., Balck, A., Klein, C. & Fleming, R. M. T. Identification of metabolites reproducibly associated with Parkinson\u2019s disease via meta-analysis and computational modelling. Npj Parkinson\u2019s Disease. 10, 126 (2024).","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"1352_CR68","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/cells11182909","volume":"11","author":"MJ Sisalli","year":"2022","unstructured":"Sisalli, M. J. et al. L-Ornithine L-Aspartate restores mitochondrial function and modulates intracellular calcium homeostasis in Parkinson\u2019s disease models. Cells 11, 2909 (2022).","journal-title":"Cells"},{"key":"1352_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2600001","volume":"260","author":"F Schuber","year":"1989","unstructured":"Schuber, F. Influence of polyamines on membrane functions. Biochem. J. 260, 1\u201310 (1989).","journal-title":"Biochem. J."},{"key":"1352_CR70","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0891-5849(91)90061-7","volume":"11","author":"E L\u00f8vaas","year":"1991","unstructured":"L\u00f8vaas, E., Carlin, G. & Spermine An anti-oxidant and anti-inflammatory agent. Free Radic. Biol. Med. 11, 455\u2013461 (1991).","journal-title":"Free Radic. Biol. Med."},{"key":"1352_CR71","first-page":"102","volume":"33","author":"LM Fiori","year":"2008","unstructured":"Fiori, L. M. & Turecki, G. Implication of the polyamine system in mental disorders. J. Psychiatry Neurosci. 33, 102\u2013110 (2008).","journal-title":"J. Psychiatry Neurosci."},{"key":"1352_CR72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry. 87, 295\u2013301 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1352_CR73","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/ph14090935","volume":"14","author":"S Plewa","year":"2021","unstructured":"Plewa, S. et al. The metabolomic approach reveals the alteration in human serum and cerebrospinal fluid composition in Parkinson\u2019s disease patients. Pharmaceuticals 14, 935 (2021).","journal-title":"Pharmaceuticals"},{"key":"1352_CR74","first-page":"1","volume":"1","author":"V \u00c7elik","year":"2018","unstructured":"\u00c7elik, V., \u00c7i\u011fdem, B., Kapancik, S., Kili\u00e7g\u00fcn, H. & Bolayir, E. The importance of increased serum ornithine levels in the pathogenes\u0131s of Alzhe\u0131mer and Park\u0131nson\u2019s d\u0131seases. Asian J. Res. Rep. Neurol. 1, 1\u20138 (2018).","journal-title":"Asian J. Res. Rep. Neurol."},{"key":"1352_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/cells11030395","volume":"11","author":"KH Chang","year":"2022","unstructured":"Chang, K. H. et al. Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of Parkinson\u2019s disease. Cells 11, 395 (2022).","journal-title":"Cells"},{"key":"1352_CR76","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.23566","volume":"26","author":"M Gabrielli","year":"2011","unstructured":"Gabrielli, M. et al. Prevalence of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov. Disord. 26, 889\u2013892 (2011).","journal-title":"Mov. Disord."},{"key":"1352_CR77","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone, P. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov. Disord. 24, 1641\u20131649 (2009).","journal-title":"Mov. Disord."},{"key":"1352_CR78","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/nu15071779","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Characteristics of the gut Microbiome and serum metabolome in patients with functional constipation. Nutrients 15, 1779 (2023).","journal-title":"Nutrients"},{"key":"1352_CR79","doi-asserted-by":"crossref","unstructured":"Perier, C. & Vila, M. Mitochondrial biology and Parkinson\u2019s disease. Cold Spring Harbor Perspect. Med. 2, a009332 (2012).","DOI":"10.1101\/cshperspect.a009332"},{"key":"1352_CR80","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1017\/S0954422419000106","volume":"32","author":"LK Murray","year":"2019","unstructured":"Murray, L. K. & Jadavji, N. M. The role of one-carbon metabolism and homocysteine in Parkinson\u2019s disease onset, pathology and mechanisms. Nutr. Res. Rev. 32, 218\u2013230 (2019).","journal-title":"Nutr. Res. Rev."},{"key":"1352_CR81","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3390\/nu15040901","volume":"15","author":"JH Kim","year":"2023","unstructured":"Kim, J. H., Jin, S., Eo, H., Oh, M. S. & Lim, Y. Two faces of Catechol-O-Methyltransferase inhibitor on One-Carbon metabolism in Parkinson\u2019s disease: A Meta-Analysis. Nutrients 15, 901 (2023).","journal-title":"Nutrients"},{"key":"1352_CR82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/metabo7030042","volume":"7","author":"J Havelund","year":"2017","unstructured":"Havelund, J., Heegaard, N., F\u00e6rgeman, N. & Gramsbergen, J. Biomarker research in Parkinson\u2019s disease using metabolite profiling. Metabolites 7, 42 (2017).","journal-title":"Metabolites"},{"key":"1352_CR83","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.3390\/ijms23073652","volume":"23","author":"ME Mycielska","year":"2022","unstructured":"Mycielska, M. E., James, E. N. & Parkinson, E. K. Metabolic alterations in cellular senescence: the role of citrate in ageing and Age-Related disease. IJMS 23, 3652 (2022).","journal-title":"IJMS"},{"key":"1352_CR84","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1038\/ncomms5708","volume":"5","author":"K Auro","year":"2014","unstructured":"Auro, K. et al. A metabolic view on menopause and ageing. Nat. Commun. 5, 4708 (2014).","journal-title":"Nat. Commun."},{"key":"1352_CR85","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/ije\/dyt094","volume":"42","author":"C Menni","year":"2013","unstructured":"Menni, C. et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int. J. Epidemiol. 42, 1111\u20131119 (2013).","journal-title":"Int. J. Epidemiol."},{"key":"1352_CR120","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cca.2018.02.022","volume":"480","author":"GN Babu","year":"2018","unstructured":"Babu, G. N. et al. Serum metabolomics study in a group of Parkinson\u2019s disease patients from Northern India. Clin. Chim. Acta. 480, 214\u2013219 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1352_CR86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40478-022-01424-6","volume":"10","author":"CE Toomey","year":"2022","unstructured":"Toomey, C. E. et al. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson\u2019s. Acta Neuropathol. Commun. 10, 134 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1352_CR87","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SSSJ Ahmed","year":"2009","unstructured":"Ahmed, S. S. S. J., Santosh, W., Kumar, S. & Christlet, H. T. T. Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16, 63 (2009).","journal-title":"J. Biomed. Sci."},{"key":"1352_CR88","doi-asserted-by":"crossref","unstructured":"Balck, A. et al. The role of dopaminergic medication and specific pathway alterations in idiopathic and PRKN\/PINK1-mediated Parkinson\u2019s disease. Sci. Adv. 11(20), eadp7063 (2025)","DOI":"10.1126\/sciadv.adp7063"},{"key":"1352_CR89","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-024-03218-0","volume":"21","author":"C Otto","year":"2024","unstructured":"Otto, C. et al. Comprehensive analysis of the cerebrospinal fluid and serum metabolome in neurological diseases. J. Neuroinflamm. 21, 234 (2024).","journal-title":"J. Neuroinflamm"},{"key":"1352_CR90","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12035-021-02657-7","volume":"59","author":"X Li","year":"2022","unstructured":"Li, X., Fan, X. Y., Yang, H. T. & Liu, Y. F. Review of Metabolomics-Based biomarker research for Parkinson\u2019s disease. Mol. Neurobiol. 59, 1041\u20131057 (2022).","journal-title":"Mol. Neurobiol."},{"key":"1352_CR91","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2020","unstructured":"Jim\u00e9nez-Jim\u00e9nez, F. J., Alonso-Navarro, H., Garc\u00eda-Mart\u00edn, E. & Ag\u00fandez, J. A. G. Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur. J. Neurol. 27, 2336\u20132347 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1352_CR92","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10072-019-04143-4","volume":"41","author":"S Kumari","year":"2020","unstructured":"Kumari, S. et al. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson\u2019s disease and healthy controls. Neurol. Sci. 41, 1201\u20131210 (2020).","journal-title":"Neurol. Sci."},{"key":"1352_CR93","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1210\/jc.2006-2215","volume":"92","author":"F Magkos","year":"2007","unstructured":"Magkos, F., Patterson, B. W., Mohammed, B. S., Klein, S. & Mittendorfer, B. Women produce fewer but Triglyceride-Richer very Low-Density lipoproteins than men. J. Clin. Endocrinol. Metabolism. 92, 1311\u20131318 (2007).","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"1352_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/clinchem\/42.4.515","volume":"42","author":"JH Contois","year":"1996","unstructured":"Contois, J. H. et al. Reference intervals for plasma Apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham offspring study. Clin. Chem. 42, 515\u2013523 (1996).","journal-title":"Clin. Chem."},{"key":"1352_CR95","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1373\/clinchem.2004.032763","volume":"50","author":"DS Freedman","year":"2004","unstructured":"Freedman, D. S. et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham study. Clin. Chem. 50, 1189\u20131200 (2004).","journal-title":"Clin. Chem."},{"key":"1352_CR96","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/clinchem\/44.8.1641","volume":"44","author":"I Jungner","year":"1998","unstructured":"Jungner, I. et al. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the world health Organization\u2013International federation of clinical chemistry first international reference materials. Clin. Chem. 44, 1641\u20131649 (1998).","journal-title":"Clin. Chem."},{"key":"1352_CR97","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2004.05.018","volume":"176","author":"JL Johnson","year":"2004","unstructured":"Johnson, J. L. et al. Gender and Racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 176, 371\u2013377 (2004).","journal-title":"Atherosclerosis"},{"key":"1352_CR98","doi-asserted-by":"crossref","unstructured":"Konz, T. et al. Sex-Specific Associations of Blood-Based Nutrient Profiling With Body Composition in the Elderly. Front. Physiol. 9, 01935 (2018).","DOI":"10.3389\/fphys.2018.01935"},{"key":"1352_CR99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/acs.jproteome.7b00404","volume":"17","author":"A Vignoli","year":"2018","unstructured":"Vignoli, A., Tenori, L., Luchinat, C. & Saccenti, E. Age and sex effects on plasma metabolite association networks in healthy subjects. J. Proteome Res. 17, 97\u2013107 (2018).","journal-title":"J. Proteome Res."},{"key":"1352_CR100","doi-asserted-by":"publisher","first-page":"173862","DOI":"10.1016\/j.ejphar.2021.173862","volume":"895","author":"B Vaidya","year":"2021","unstructured":"Vaidya, B., Dhamija, K., Guru, P. & Sharma, S. S. Parkinson\u2019s disease in women: mechanisms underlying sex differences. Eur. J. Pharmacol. 895, 173862 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"1352_CR101","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.yfrne.2019.100817","volume":"56","author":"LAM Galea","year":"2020","unstructured":"Galea, L. A. M., Choleris, E., Albert, A. Y. K., McCarthy, M. M. & Sohrabji, F. The promises and pitfalls of sex difference research. Front. Neuroendocrinol. 56, 100817 (2020).","journal-title":"Front. Neuroendocrinol."},{"key":"1352_CR102","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.pt.2024.09.006","volume":"40","author":"J Sellau","year":"2024","unstructured":"Sellau, J. et al. Immunological clues to sex differences in parasitic diseases. Trends Parasitol. 40, 1029\u20131041 (2024).","journal-title":"Trends Parasitol."},{"key":"1352_CR103","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1042\/CS20150586","volume":"130","author":"S Westerman","year":"2016","unstructured":"Westerman, S. & Wenger, N. K. Women and heart disease, the underrecognized burden: sex differences, biases, and unmet clinical and research challenges. Clin. Sci. 130, 551\u2013563 (2016).","journal-title":"Clin. Sci."},{"key":"1352_CR104","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-024-49196-y","volume":"15","author":"L Caldi Gomes","year":"2024","unstructured":"Caldi Gomes, L. et al. Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target. Nat. Commun. 15, 4893 (2024).","journal-title":"Nat. Commun."},{"key":"1352_CR105","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/JOE-15-0533","volume":"229","author":"ME Cleasby","year":"2016","unstructured":"Cleasby, M. E., Jamieson, P. M. & Atherton, P. J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J. Endocrinol. 229, R67\u2013R81 (2016).","journal-title":"J. Endocrinol."},{"key":"1352_CR106","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yfrne.2017.09.002","volume":"50","author":"JC Jurado-Coronel","year":"2018","unstructured":"Jurado-Coronel, J. C. et al. Sex differences in Parkinson\u2019s disease: features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front. Neuroendocrinol. 50, 18\u201330 (2018).","journal-title":"Front. Neuroendocrinol."},{"key":"1352_CR107","doi-asserted-by":"crossref","unstructured":"Liu, B. & Dluzen, D. E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson\u2019s disease. Clin. Experimental Pharmacol. Physiol. 34, 555\u2013565 (2007).","DOI":"10.1111\/j.1440-1681.2007.04616.x"},{"key":"1352_CR108","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/jnr.21977","volume":"87","author":"M Morissette","year":"2009","unstructured":"Morissette, M. & Di Paolo, T. Effect of estradiol on striatal dopamine activity of female Hemiparkinsonian monkeys. J. Neurosci. Res. 87, 1634\u20131644 (2009).","journal-title":"J. Neurosci. Res."},{"key":"1352_CR109","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2014.03.010","volume":"259","author":"KM Smith","year":"2014","unstructured":"Smith, K. M. & Dahodwala, N. Sex differences in Parkinson\u2019s disease and other movement disorders. Exp. Neurol. 259, 44\u201356 (2014).","journal-title":"Exp. Neurol."},{"key":"1352_CR110","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1212\/WNL.42.11.2111","volume":"42","author":"PA LeWitt","year":"1992","unstructured":"LeWitt, P. A. et al. Markers of dopamine metabolism in Parkinson\u2019s disease. Neurology 42, 2111\u20132111 (1992).","journal-title":"Neurology"},{"key":"1352_CR111","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/ene.15801","volume":"30","author":"R Bovenzi","year":"2023","unstructured":"Bovenzi, R. et al. Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study. Eur. J. Neurol. 30, 1983\u20131990 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1352_CR112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13293-025-00692-w","volume":"16","author":"SL Schaffner","year":"2025","unstructured":"Schaffner, S. L., Tosefsky, K. N., Inskter, A. M., Appel-Cresswell, S. & Schulze-Hentrich, J. M. Sex and gender differences in the molecular etiology of Parkinson\u2019s disease: considerations for study design and data analysis. Biology Sex. Differences. 16, 7 (2025).","journal-title":"Biology Sex. Differences"},{"key":"1352_CR113","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/metabo12121277","volume":"12","author":"T R\u00f6ssler","year":"2022","unstructured":"R\u00f6ssler, T. et al. Quantitative serum NMR spectroscopy stratifies COVID-19 patients and sheds light on interfaces of host metabolism and the immune response with cytokines and clinical parameters. Metabolites 12, 1277 (2022).","journal-title":"Metabolites"},{"key":"1352_CR114","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbagen.2016.06.018","volume":"1860","author":"R Paul","year":"2016","unstructured":"Paul, R. & Borah, A. L-DOPA-induced hyperhomocysteinemia in Parkinson\u2019s disease: elephant in the room. Biochim. Et Biophys. Acta (BBA) - Gen. Subj. 1860, 1989\u20131997 (2016).","journal-title":"Biochim. Et Biophys. Acta (BBA) - Gen. Subj."},{"key":"1352_CR115","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/nu14030599","volume":"14","author":"K Kaleck\u00fd","year":"2022","unstructured":"Kaleck\u00fd, K., Ashcraft, P. & Bottiglieri, T. One-Carbon metabolism in Alzheimer\u2019s disease and Parkinson\u2019s disease brain tissue. Nutrients 14, 599 (2022).","journal-title":"Nutrients"},{"key":"1352_CR116","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13229-021-00423-z","volume":"12","author":"Y Kato","year":"2021","unstructured":"Kato, Y. et al. Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in Oxytocin efficacy for autism social core symptoms. Mol. Autism. 12, 15 (2021).","journal-title":"Mol. Autism"},{"key":"1352_CR117","doi-asserted-by":"crossref","unstructured":"Dimitri, G. M., Meoni, G., Tenori, L., Luchinat, C. & Li\u00f3, P. NMR Spectroscopy Combined with Machine Learning Approaches for Age Prediction in Healthy and Parkinson\u2019s Disease Cohorts through Metabolomic Fingerprints. Appl. Sci. 12, 8954 (2022).","DOI":"10.3390\/app12188954"},{"key":"1352_CR118","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00415-008-0763-4","volume":"255","author":"J Prestel","year":"2008","unstructured":"Prestel, J. et al. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J. Neurol. 255, 643\u2013648 (2008).","journal-title":"J. Neurol."},{"key":"1352_CR119","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SSSJ Ahmed","year":"2009","unstructured":"Ahmed, S. S. S. J., Santosh, W., Kumar, S. & Christlet, H. Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16, 63 (2009).","journal-title":"J. Biomed. Sci."},{"key":"1352_CR122","doi-asserted-by":"publisher","first-page":"115815","DOI":"10.1016\/j.jpba.2023.115815","volume":"238","author":"R Conde","year":"2024","unstructured":"Conde, R. et al. NMR analysis seeking for cognitive decline and dementia metabolic markers in plasma from aged individuals. J. Pharm. Biomed. Anal. 238, 115815 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"1352_CR123","doi-asserted-by":"publisher","first-page":"104670","DOI":"10.1016\/j.neuint.2020.104670","volume":"134","author":"S Kumari","year":"2020","unstructured":"Kumari, S. et al. Metabolomic analysis of serum using proton NMR in 6-OHDA experimental PD model and patients with PD. Neurochem. Int. 134, 104670 (2020).","journal-title":"Neurochem. Int."},{"key":"1352_CR124","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00424-017-2077-9","volume":"470","author":"K Sakuma","year":"2018","unstructured":"Sakuma, K. & Yamaguchi, A. Recent advances in Pharmacological, hormonal, and nutritional intervention for sarcopenia. Pflugers Arch. - Eur. J. Physiol. 470, 449\u2013460 (2018).","journal-title":"Pflugers Arch. - Eur. J. Physiol."},{"key":"1352_CR125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.06.020","volume":"56","author":"AH Tan","year":"2018","unstructured":"Tan, A. H. et al. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 56, 58\u201364 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1352_CR126","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10072-020-04601-4","volume":"42","author":"MCL da Luz","year":"2021","unstructured":"da Luz, M. C. L., Bezerra, G. K. A., Asano, A. G. C., de Chaves, M. C. & Cabral, P. C. Determinant factors of sarcopenia in individuals with Parkinson\u2019s disease. Neurol. Sci. 42, 979\u2013985 (2021).","journal-title":"Neurol. Sci."},{"key":"1352_CR127","doi-asserted-by":"publisher","first-page":"147118","DOI":"10.1016\/j.brainres.2020.147118","volume":"1748","author":"B Toczylowska","year":"2020","unstructured":"Toczylowska, B., Zieminska, E., Micha\u0142owska, M., Chalimoniuk, M. & Fiszer, U. Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients \u2013 In vitro and in vivo NMR spectroscopy studies. Brain Res. 1748, 147118 (2020).","journal-title":"Brain Res."},{"key":"1352_CR128","doi-asserted-by":"crossref","unstructured":"Vignoli, A. et al., High-Throughput Metabolomics by 1D NMR. Angew. Chem. Int. Ed. 58, 968\u2013994 (2019).","DOI":"10.1002\/anie.201804736"},{"key":"1352_CR129","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.nbt.2019.04.004","volume":"52","author":"V Ghini","year":"2019","unstructured":"Ghini, V., Quaglio, D., Luchinat, C. & Turano, P. NMR for sample quality assessment in metabolomics. New Biotechnol. 52, 25\u201334 (2019).","journal-title":"New Biotechnol."},{"key":"1352_CR130","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.trac.2018.10.036","volume":"120","author":"PG Takis","year":"2019","unstructured":"Takis, P. G., Ghini, V., Tenori, L., Turano, P. & Luchinat, C. Uniqueness of the NMR approach to metabolomics. TRAC Trends Anal. Chem. 120, 115300 (2019).","journal-title":"TRAC Trends Anal. Chem."},{"key":"1352_CR131","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12933-024-02363-3","volume":"23","author":"R Gil-Redondo","year":"2024","unstructured":"Gil-Redondo, R. et al. MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics. Cardiovasc. Diabetol. 23, 272 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1352_CR132","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s43856-023-00365-y","volume":"3","author":"J Kazenwadel","year":"2023","unstructured":"Kazenwadel, J. et al. Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum. Commun. Med. (Lond). 3, 145 (2023).","journal-title":"Commun. Med. (Lond)"},{"key":"1352_CR133","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov. Disord. 35, 1138\u20131144 (2020).","journal-title":"Mov. Disord."},{"key":"1352_CR134","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11682-023-00812-3","volume":"18","author":"N Upadhyay","year":"2024","unstructured":"Upadhyay, N. et al. Fronto-striatal alterations correlate with apathy severity in behavioral variant frontotemporal dementia. Brain Imaging Behav. 18, 66\u201372 (2024).","journal-title":"Brain Imaging Behav."},{"key":"1352_CR135","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-017-0314-2","volume":"10","author":"F Jessen","year":"2018","unstructured":"Jessen, F. et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer\u2019s disease (DELCODE). Alzheimers Res. Ther. 10, 15 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"1352_CR136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/alz.12674","volume":"19","author":"F Jessen","year":"2023","unstructured":"Jessen, F. et al. Subjective cognitive decline and stage 2 of alzheimer disease in patients from memory centers. Alzheimer\u2019s Dement. 19, 487\u2013497 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1352_CR137","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jgs.12742","volume":"62","author":"P Julayanont","year":"2014","unstructured":"Julayanont, P., Brousseau, M., Chertkow, H., Phillips, N. & Nasreddine, Z. S. Montreal cognitive assessment memory index score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer\u2019s disease. J. Am. Geriatr. Soc. 62, 679\u2013684 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1352_CR138","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/mds.10171","volume":"17","author":"F Tison","year":"2002","unstructured":"Tison, F. et al. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson\u2019s disease. Mov. Disord. 17, 701\u2013709 (2002).","journal-title":"Mov. Disord."},{"key":"1352_CR139","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1037\/1040-3590.10.2.83","volume":"10","author":"DJA Dozois","year":"1998","unstructured":"Dozois, D. J. A., Dobson, K. S. & Ahnberg, J. L. A psychometric evaluation of the Beck depression Inventory\u2013II. Psychol. Assess. 10, 83\u201389 (1998).","journal-title":"Psychol. Assess."},{"key":"1352_CR140","doi-asserted-by":"crossref","unstructured":"Trautwein, C. Quantitative Blood Serum IVDr NMR Spectroscopy in Clinical Metabolomics of Cancer, Neurodegeneration, and Internal Medicine. in Clinical Metabolomics: Methods and Protocols (eds. Giera, M. & S\u00e1nchez-L\u00f3pez, E.) 427\u2013443Springer US, New York, NY, (2025).","DOI":"10.1007\/978-1-0716-4116-3_24"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01352-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:05:44Z","timestamp":1747883144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01352-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01352-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GeB and CT report a research grant by Bruker BioSpin GmbH & Co. KG. CW and HS are employed at Bruker BioSpin GmbH & Co. KG, Ettlingen, Germany. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The project was carried out in compliance with the Helsinki Declaration, and all participants provided written informed consent. Sample collection and study design were approved by the local Ethics Committee of Eberhard Karls University of T\u00fcbingen (ethics numbers 226\/2021B02 and 199\/2011BO1), Germany. Regarding the Cohort 2 of the present study, the following ethic numbers are of reference \u2013 numbers 311\/14 (status year 2021) and 312\/14 (status year 2018). Harmonized voting was carried out at the Lead Ethics Bonn.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"The data were provided by the study group of DESCRIBE and DANCER studies of the clinical research of the German Center for Neurodegenerative Diseases (DZNE). And data were provided by the study groups of TUEPAC study at the University Hospital of Tuebingen. The clinical data supporting the findings are available upon request to: thomas.gasser@uni-tuebingen.de.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Metadata declaration"}}],"article-number":"17738"}}